IDEAYA Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 124
- Market Cap
- $3.3B
- Website
- http://www.ideayabio.com
- Introduction
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and ...
IDEAYA Biosciences to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM) on September 23, 2024, at 8:00 a.m. ET via investor webcast.
IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
Douglas B. Snyder joins IDEAYA Biosciences as SVP, General Counsel, bringing over 25 years of legal experience from GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDA.
Risk Adjusted Net Present Value: What is the current valuation of Ideaya Biosciences's IDE-397
IDE-397, targeting tumors with MTAP gene deletion via MAT2A inhibition, is forecasted to generate $81 mn in annual revenue by 2036 in the US. Developed by Ideaya Biosciences, the drug is part of a synthetic lethality platform and is administered orally for various cancers. Ideaya reported a revenue decrease of 54.1% in FY2023, with a net loss of $113 mn. The rNPV model, considering R&D risks, is available for purchase.
© Copyright 2025. All Rights Reserved by MedPath